Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:8/11/2008

roy the tumor and the tumor blood vessels. Bavituximab currently is in two separate Phase II combination therapy trials for the treatment of advanced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. Peregrine recently reported that a Phase II trial assessing the combination of bavituximab and docetaxel in patients with metastatic breast cancer had achieved the pre-specified Stage A primary efficacy endpoint needed to expand the trial to the second stage. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that th
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x5lz9r/global_poc ... POC Diagnostics Market 2015-2019" report to their offering. ... POC Diagnostics market to grow at a CAGR of ... POC diagnostics are IVD devices and tools used for ... The use of these devices helps in the rapid ...
(Date:3/3/2015)...  Columbia Laboratories, Inc. (Nasdaq: CBRX ) ... specialty pharmaceutical company focused on pharmaceuticals for women,s health, ... Annual ROTH Conference, which will take place from March ... Dana Point, California . Management,s presentation will take ... Time (12:00 p.m. Eastern Time) in the Promenade room. ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... the "Global Ultrasound Equipment Market 2015-2019" ... The Global Ultrasound Equipment market to grow ... 2014-2019 Ultrasound equipment are used to ... are extensively used by cardiologists, radiologists, surgeons, obstetricians, ...
Breaking Medicine Technology:Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2Global Ultrasound Equipment Market 2015-2019: Rise in Number of MI Diagnostic Procedures with GE Healthcare, Phillips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2
... Sept. 2, 2011 The overall success of ... markets sector. Access to formularies and relationships with ... growth for pharmaceutical organizations. Given the importance of ... account executives, performance is a critical undertaking for ...
... Cox Business have partnered to make a new, diagnostically ... the Valley and across the state at the same ... first dedicated outpatient offering of breast tomosynthesis in Arizona ... Sub-specialty trained radiologists at SimonMed can now ...
Cached Medicine Technology:Assessing the Performance of Account Executives for the Critical Managed Markets Sector 2SimonMed and Cox Business Bring Breast Tomosynthesis to Arizona 2
(Date:3/3/2015)... Il. (PRWEB) March 03, 2015 The ... is set to reveal the world’s first fully integrated ... are breathing and controls an air purifier to remove ... user informed, and in control, via phone, tablet or ... purifiers in over 50 countries worldwide, will unveil its ...
(Date:3/3/2015)... UK (PRWEB) March 03, 2015 The ... growth of the augmentation market. The wearable augmentation sector ... terms of size in the upcoming years. , ... market owing to a big number of new products ... North American region, high technological advancements as well as ...
(Date:3/3/2015)... Daylight Savings Time may lead to your ... tips for parents. , Parents and their children may feel ... when they set their clocks forward one hour for Daylight ... -- one hour earlier -- you will have already lost ... thinking about “sleep hygiene” for their kids and teens this ...
(Date:3/3/2015)... Sunday, March 1, through Saturday, March 7, is ... year, every region of the country is at risk for ... Insurance is sharing the following tips from the Centers ... you safe in the event of severe weather: , Winter ... frequently to prevent loss of body heat. Wear warm, loose-fitting, ...
(Date:3/3/2015)... — (PRWEB) March 03, 2015 -- vRad ... and radiology practice, today announced that Arlene Sussman, MD, ... will host a live webinar to explore how telemedicine ... specialized breast imaging services for women virtually anywhere. Click ... Breast Imaging Service Line” on March 4, 2015 at ...
Breaking Medicine News(10 mins):Health News:Smart sensor and air purifier interconnect to track and trap dust, pollen and dangerous particles in home and workplace air 2Health News:Human Augmentation Market to Pose 43.5% CAGR Through 2020, States MarketsandMarkets in its New Research Study Now Available at MarketPublishers.com 2Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2Health News:Amica Insurance Has Tips for National Severe Weather Preparedness Week 2Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 2Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 3Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 4
Medtronic, Inc., a world leader in therapies for restoring people with chronic conditions to full life, introduces the AT500 Pacing System for the management of atrial tachyarrhythmias and bradycardi...
The first-ever pacemaker to include Managed Ventricular Pacing (MVP), the EnRhythm Pacing System promotes intrinsic conduction and is clinically proven to significantly reduce unnecessary right ventr...
... 3000Dx (GCS3000Dx) is the first microarray instrumentation ... consists of the FS450Dx Fluidics Station which ... array, the GCS3000Dx Scanner with AutoLoader Dx ... to be scanned without operator intervention, and ...
... compact system capable of B-mode, M-mode, ... intuitive operation, high mobility, and exceptional ... incorporates an alphanumeric keyboard, several one-touch ... toggle keys for application specific functions. ...
Medicine Products: